VDPHL01 / Veradermics - LARVOL DELTA

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P3 | N=552 | Recruiting | Sponsor: Veradermics, Inc. | Trial completion date: Mar 2027 ➔ Jan 2028 | Trial primary completion date: Mar 2027 ➔ Jun 2027

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: Veradermics, Inc. | Trial completion date: Nov 2026 ➔ Jul 2027

Trial completion date • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males and Females With AGA (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Veradermics, Inc. | Trial primary completion date: Feb 2026 ➔ Aug 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2/3 | N=480 | Active, not recruiting | Sponsor: Veradermics, Inc. | Trial primary completion date: Jul 2026 ➔ Feb 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Comparative Efficacy of an Investigational Oral Minoxidil Extended-Release Tablet Versus Existing Minoxidil Formulations in Androgenetic Alopecia: A Blinded Retrospective IGA Analysis (EADV 2025) - "Introduction The use of minoxidil for the treatment of androgenetic alopecia (AGA), both as a topical and as an immediate release (IR) oral tablet, has increased in recent years; however, there are still no oral formulations of minoxidil that are FDA approved for AGA. Pending further clinical development, these findings suggest VDPHL01 is a potential best-in-class treatment for AGA. Study limitations include potential differences in baseline characteristics of subjects across trials and inherent limitations in retrospective photography-based review methodologies."

Late-breaking abstract • Retrospective data • Alopecia • Immunology

Safety and Efficacy of VDPHL01 in Males and Females With AGA (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Veradermics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2026 ➔ Aug 2026

Enrollment closed • Trial completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2/3 | N=480 | Active, not recruiting | Sponsor: Veradermics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P3 | N=552 | Recruiting | Sponsor: Veradermics, Inc.

New P3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P3 | N=480 | Recruiting | Sponsor: Veradermics, Inc.

New P3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males and Females with AGA (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Veradermics, Inc. | N=20 ➔ 70 | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Aug 2025 ➔ Feb 2026

Enrollment change • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of VDPHL01 in Males with AGA (clinicaltrials.gov) - P2/3 | N=480 | Recruiting | Sponsor: Veradermics, Inc.

New P2/3 trial • Alopecia • Dermatology • Immunology

Safety and Efficacy of VDPHL01 in Males With AGA (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Veradermics, Inc.

New P2 trial • Alopecia • Dermatology • Immunology